NLRP3 and multiple sclerosis: More recently, a newly developed, potent, and selective inhibitor of NLRP3, MCC950, significantly inhibited IL-1β production in an animal model of multiple sclerosis, which could be a potential therapeutic agent for other NLRP3-associated neuroinflammatory conditions [186].